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The complexity of resource allocation for health
 In The Lancet Global Health, Stephen Resch and 
colleagues’ study benchmarks 12 countries’ government 
expenditure on HIV/AIDS.1 This important research 
emphasises that many governments are not meeting 
spending goals, and in many countries the ﬁ nancing 
gaps are so great that, even if they met the spending 
goals, expenditure would still fall short of what is needed 
(expenditure would cover only 64% of estimated future 
funding requirements, leaving a gap of around a third of 
the total US$7·9 billion needed). Quantiﬁ cation of the 
gaps in domestic spending encourages us to consider 
whether the amount of funding is appropriate and how 
much more could and should be done to ﬁ ght HIV/AIDS. 
The important question of how governments make 
allocation choices also comes to the forefront. The 
aim of this Comment is to draw attention to the many 
dimensions that contribute to the complexity of these 
decisions on health resource allocation.
The allocation of governmental resources is a multi-
faceted balance between competing tradeoﬀ s. In the 
12 low-income and middle-income countries focused 
on by Resch and colleagues, government resources 
are sparse.2 Taking this into consideration, Resch and 
colleagues’ benchmarking exercise uses internationally 
set targets, economic forecasts, and burden of disease 
estimates to establish the appropriateness of spending 
patterns. In addition to these factors, governments 
face several competing considerations when allocating 
health resources. We believe that this complexity 
boils down to ﬁ ve key factors: disease burden, cost-
eﬀ ectiveness, external parties’ ability and willingness to 
pay, intertemporal tradeoﬀ s, and health equity. 
The disease burden, as noted by Resch and colleagues, 
should aﬀ ect how resources are allocated in the health 
sector. In general, a larger avertable health burden 
necessitates more resources. Ongoing improvements 
and timeliness of global burden of disease data can be 
an informative diagnostic approach for policymakers 
and researchers alike for this purpose.3 
Cost-eﬀ ectiveness is the mechanism that transforms 
ﬁ nancial resources into health gains. Inherently, 
attainment of the greatest health eﬀ ect possible with 
the ﬁ nite resources available is of the utmost importance 
to policy makers. A push to prioritise the most cost-
eﬀ ective interventions can lead to substantive health 
gains.4 However, more work is needed to develop 
comparable, comprehensive, and context-speciﬁ c cost-
eﬀ ectiveness estimates, since they are not available for 
some causes and many interventions, especially in low-
income and middle-income countries. 
External parties’ ability and willingness to fund 
health interventions is also an important factor in 
how governments decide on their spending priorities. 
Historically, development partners have funded 
prevention and treatment for a key group of diseases.5 
Furthermore, a diverse set of barriers prevents the 
private sector from providing a comprehensive set of 
services to all people.6–8 Governments have a part to 
play in addressing the disease burden that is ignored or 
only partly covered by the private sector and donors, 
and governments are wise to spend in a manner 
complementary to other major funders.
Governments also consider intertemporal trade-
oﬀ s when investing in health. Investments such 
as surveillance, workforce development, disease 
eradication, and building of hospitals and clinics have 
potential to prevent death and disability in the future, 
although funding for these interventions is necessary 
now. Implementation of these projects needs a balance 
between future and present health gains. 
Finally, allocation decisions must strive to achieve 
health equity. Governments need to protect those least 
able to protect themselves—often women, children, 
poor people, and otherwise marginalised groups. 
In many cases, to reach these populations entails 
investments that are not the most cost-eﬀ ective or not 
concentrated on the greatest share of burden but are 
still of great importance. 
In view of the many factors that aﬀ ect how 
governments allocate their resources for health, what 
good are international benchmarks? First, as evidenced 
by the Millennium Development Goals, international 
goals, targets, and benchmarks align eﬀ orts, focus 
the public’s attention, and mobilise external funding 
streams.9 Second, these eﬀ orts stimulate the ongoing 
conversation about the rationale underpinning 
governmental allocation decisions, including the need 
for additional data and analysis. The work by Resch and 
colleagues draws attention to 12 governments that are 
falling short of some HIV/AIDS spending targets, and 
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brings special attention to important gaps that would 
remain even if these countries met the targets. These 
allocation decisions are underpinned by complex and 
competing considerations, and many explanations exist 
for a range of health spending priorities. Additional data 
and research in these areas will help us to disentangle 
the complexity of these decisions and better establish 
whether governments, along with the international 
community, are on track to meet population health 
targets.
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